|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
This is relevant as the recently licensed CGRP antagonists are likely to change current treatment schemes for migraine, which strongly depends also on the comorbidities.
|
31828875 |
2020 |
|
Migraine Disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The neuropeptide CGRP, acting through the G-protein coupled receptor CALCRL and its coreceptor RAMP1, plays a key role in migraines, which has led to the clinical development of several inhibitory compounds.
|
31756985 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed a close relationship between the CGRP containing C-fibers and the Aδ-fibers containing the CGRP-receptor elements, suggesting a point of axon-axon interaction for the released CGRP and a site of action for gepants and the novel mAbs to alleviate migraine.
|
31718551 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CGRP plays a major role in the pathophysiology of migraine.
|
31589869 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-review.
|
31547694 |
2020 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Ubrogepant is a novel, oral calcitonin gene-related peptide (CGRP) receptor antagonist in development for the acute treatment of migraine.
|
31537107 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Background:</b> Research has indicated that calcitonin gene-related peptide (CGRP) receptor antagonists can be effective in the acute treatment of migraine.
|
31354502 |
2019 |
|
Migraine Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In conclusion, the progresses in migraine management have been reached with the development of emerging agonists of 5-HT receptors and novel antagonists of CGRP receptors.
|
31208068 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Monoclonal antibodies (mAbs) targeting the CGRP pathway are safe and efficacious therapies for the prevention of migraine.
|
31159727 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CLR/RAMP1, or CGRP receptor, antagonists have been developed for the treatment of migraine headache and osteoarthritis pain; whereas CLR/RAMP2, or ADM receptor, antagonists are being developed for the treatment of tumor growth/metastasis.
|
31150417 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Novel therapeutic perspectives in migraine includes biotechnological drugs directed against molecules (such as CGRP and its receptor) that cause vasodilatation at the peripheral level of the meningeal blood vessels and reflex stimulation of the parasympathetic system.
|
31101004 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, erenumab, a monoclonal antibody antagonist of the CGRP receptor, administered as a once monthly dose of 70 or 140 mg has been approved for the preventive treatment of migraine in adults.
|
31085251 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
This article reviews the available data for first- and second-generation CGRP receptor antagonists, the role of CGRPs in human physiology and migraine pathophysiology and the possible mechanism of action and safety of CGRP-targeted drugs.
|
31081399 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The evolution of CGRP migraine science gave impetus to the development of peripherally acting drugs that could modulate CGRP chronically to prevent frequent episodic and chronic migraine.
|
31020659 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
During the past year monoclonal antibodies against CGRP or the CGRP receptor have emerged as the most promising targets for migraine therapy, and at the same time established the strong involvement of CGRP in the pathophysiology of migraine.
|
30989485 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
These data implicate the dura mater as a primary location of action for CGRP in migraine and suggest that female-specific mechanisms downstream of CGRP receptor activation contribute to the higher prevalence of migraine in women.
|
30962278 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.
|
30661365 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently.
|
30656853 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The calcitonin gene-related peptide (CGRP) receptor system has emerged as an important drug target for migraine.
|
30527443 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
To evaluate the efficacy of fremanezumab, a selective monoclonal CGRP ligand antibody, during the first 3 weeks of therapy in patients with high-frequency episodic migraine (HFEM) to relieve migraine headaches and associated symptoms and to reduce use of acute migraine medications.
|
30450545 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The US Food and Drug Administration (FDA) approved erenumab-aooe, an anti-CGRP receptor monoclonal antibody, for the prevention of migraine on May 17, 2018.
|
30403405 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Its central role in migraine was proven pharmacologically by the development of CGRP receptor antagonists.
|
30311143 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The first anti-CGRP treatment, an intravenous CGRP-receptor antagonist or gepant, olcegepant, was described as effective in terminating migraines in humans in 2004.
|
30242830 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Amgen and Novartis are developing erenumab (AIMOVIG™, erenumab-aooe)-a fully human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist-for the prevention of migraine.
|
29968151 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
In testing of the antimigraine drugs the capsaicin-induced skin redness with activated TRPV1 receptors in sensory neurons associated with the release of the migraine mediator CGRP has already been widely used.
|
29915934 |
2018 |